Keep buying Aurora Cannabis, says Canaccord Genuity

A quarter that fell below his expectations isn’t dampening Canaccord Genuity analyst Neil Maruoka’s enthusiasm for Aurora Cannabis (TSXV:ACB).

Yesterday, Aurora Cannabis reported its Q3, 2017 results. The company earned $100,000 on revenue of $5.2-million, up substantially from the $200,000 topline the company posted in the same period last year.

“Going forward, with one of the strongest cash balances in the industry, we will be able to execute on our aggressive expansion plans, both domestically and internationally, as we have done successfully with the acquisition of Peloton and our participation in the IPO of Australia’s first licensed cannabis company, Cann Group,” said CEO said Terry Booth. “Finally, as we are maturing as an organization, we have added considerable strength to the management team with the appointments of a chief financial officer and director of Quebec Affairs. These new team members will add important additional senior executive capacity as we pursue our goals and execute our growth strategy.”

Maruoka says he had modeled revenue of $7.7-million, but notes that Aurora’s sales run rate continues to track higher into the fourth quarter and is now above $2-million a month. The analyst says that with aggressive expansion plans and a cash warchest of $186-million, he would still be a buyer of the stock. The analyst today maintained his “Speculative Buy” rating and one-year price target of $3.25 on Aurora, implying a return of 29 per cent at the time of publication. But he says impending legalization may send his target higher.

“Our un-risked analysis for Aurora suggests a valuation in excess of $5.00 per share if marijuana is legalized in Canada, supporting our SPECULATIVE BUY rating as the pathway to the rec market further unfolds,” he says. “We would remain buyers of the stock ahead of construction milestones for Aurora Sky.”

Maruoka thinks Aurora Cannabis will generate EBITDA of $7.9-million on revenue of $27-million in fiscal 2017. He expects these numbers will improve to EBITDA of $80.2-million on revenue of $192-million the following year.

Tagged with: acb
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is it time to sell your Byrna Technologies stock?

Roth Capital Partners analyst Matt Koranda says Byrna Technologies’ (Byrna Technologies Stock Quote, Chart, News, Analysts, Financials NASDAQ:BYRN) shift toward… [Read More]

19 hours ago

Is BCE actually an AI play?

Newhaven Asset Management analyst Rebecca Teltscher says BCE (BCE Stock Quote, Chart, News, Analysts, Financials TSX:BCE) is a defensive telecom… [Read More]

20 hours ago

This analyst nearly doubled his price target on Data Communications Management

Clarus Securities analyst Noel Atkinson says Data Communications Management’s (Data Communications Management Stock Quote, Chart, News, Analysts, Financials TSX:DCM) acquisition… [Read More]

20 hours ago

Magellan Aerospace wins huge target raise from this bank

Paradigm Capital analyst J. Marvin Wolff says Magellan Aerospace (Magellan Aerospace Stock Quote, Chart, News, Analysts, Financials TSXV:MAL) should benefit… [Read More]

20 hours ago

EnWave: Buy, Sell or Hold?

Clarus Securities analyst Noel Atkinson says EnWave’s (EnWave Stock Quote, Chart, News, Analysts, Financials TSXV:ENW) sale of a second 120-kilowatt… [Read More]

20 hours ago

WELL Health Technologies: this analyst just raised his price target

Paradigm Capital analyst Daniel Rosenberg says WELL Health Technologies’ (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) WELLSTAR… [Read More]

4 days ago